Company Overview - LeMaitre Vascular, Inc. (LMAT) is a leading owner-operator in the peripheral vascular device market with a market cap of $1.9 billion, designing and marketing over 100 specialized devices for vascular procedures outside the heart and brain [2] - The company has grown through a disciplined roll-up strategy, acquiring more than 30 subsidiaries, which allows it to leverage a fragmented market and achieve operational synergies [3] Financial Performance - LeMaitre has historically achieved revenue growth at a CAGR of 12–15% and EPS growth at a CAGR of 19–21%, with forward growth estimates remaining attractive [5] - The company enjoys a 71% gross margin, 21% return on invested capital (ROIC), and strong free cash flow conversion, indicating robust financial health [4] Competitive Advantage - LeMaitre benefits from a durable competitive advantage due to its highly specialized products, regulatory barriers, and strong relationships with surgeons [4] - The founder-led management under George W. LeMaitre aligns shareholder interests with long-term growth, having delivered over 1,500% returns since the 2006 IPO [3] Growth Drivers - The company has dual growth engines: organic demand driven by an aging global population and minimally invasive surgery trends, alongside inorganic growth through acquisitions [4] - Valuation metrics suggest reasonable upside, trading below its 10-year average forward P/E, with expected returns of 11–16% per year [5] Investment Thesis - LeMaitre Vascular exemplifies a high-quality, patient, and compounding business in a resilient and growing medical device niche, supported by strong fundamentals and disciplined capital allocation [5] - The Total Quality Score of 8/10 reflects its status as an exceptional investment opportunity [5]